Genetic Variants of Selected Genes in Colo-Rectal Cancer Patients.

Summary

Colorectal cancers (CRC) are the third most common human malignancy, and are also the leading cause of cancer related deaths worldwide. Early detection of premalignant lesions such as adenomatous polyps has decreased the risk of CRCs; however, cases which are initially undetected and progress to advanced CRC with distant metastasis are still unfortunately incurable. The development of CRC is a complex and heterogeneous process arising from an interaction between multiple etiological factors, including genetic factors and environmental factors such as diet and lifestyle. The challenges are to understand the molecular basis of individual susceptibility to colorectal cancer and to determine factors that initiate the development of the tumor, drive its progression, and determine its responsiveness or resistance to antitumor agents. Next generation sequencing(NGS)-driven genomic studies are already reporting novel features of cancer genomes beyond the traditional mutational categories. Recent advance in sequencing technology has enabled comprehensive profiling of genetic alterations in CRC.These methods are facilitating an increase in the efficiency and resolution of detection of each of the principal types of somatic cancer genome alterations, including nucleotide substitutions, small insertions and deletions, copy number alterations, chromosomal rearrangements,DNA methylation sequencing such as bisulfite-sequencing and microbial infections. Besides the microsatellite instability (MSI), some researchers reported novel mitochondrial mutations in the cancer genomes. NGS technology will help the investigators for understanding of entire CRC genomes and the obtained knowledge will lead to a better diagnosis and personalized targeted therapeutics for CRC management

Conditions

• Cancer Colon

Interventions

GENETIC

Whole genome sequencing

At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.

Sponsors & Collaborators

• Tanta University

  collaborator OTHER

• Sherief Abd-Elsalam

  lead OTHER

Principal Investigators

• Said Hammad abdou, Prof · Prof of clincal pathology and genetics

• Samah mosaad aboelenein, lecturer · lecturer of gastroenterology and hepatology

• Asem Elfert, Prof · Prof of gastroenterology and hepatology

• Sherief Abd-Elsalam, Lecturer · lecturer of gastroenterology and hepatology

• Walaa Elkhalawany, Lecturer · lecturer of gastroenterology and hepatology

• Nehal Elmashad, Prof · Prof of oncology

• Mohamed Labib Salem, Prof · Prof of immunology and genetics

• Abdel-Aziz Zidan, lecturer · lecturer of immunology and genetics

• Amira youssef, lecturer · Lecturer of clinical pathology

• Ayman Elsaka, prof · Prof of pathology

• Gamal Mousa, prof · Prof of general surgery

• Khalil Abas, Prof · Prof of public health and medical statistics

• Osama Elkhadrawy, Prof · Prof of general surgery

• Eman Ebrahim Ebrahim Farghal, Ph.D. · Tanta University

• Marwa H Saied, Ph.D. · Tanta University

Eligibility

Min Age

10 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2015-07-31

Primary Completion

2019-12-31

Completion

2019-12-31

Countries

• Egypt

Study Locations